<DOC>
	<DOC>NCT01515280</DOC>
	<brief_summary>The aim of this study is to have those patients taking part in the Clinical trial-: A Multicentre, Double-Blind, Placebo-Controlled, Pivotal Study of the Efficacy and Safety of Oral Theobromine in the Management of Cough. Complete the Hull Airway Reflux Questionnaire (HARQ) at randomisation and repeat the questionnaire at the end of the 14 day treatment period. The investigators hope to demonstrate a clinically significant change in HARQ scores of at least 16 points from before and after treatment. Furthermore the investigators would hope to show a significantly improved HARQ score in patients on the BC036 arm of the study compared to the placebo arm.</brief_summary>
	<brief_title>Hull Airway Reflux Questionnaire Scores Following Cough Treatment</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>1. Male/females meeting eligibility criteria for study: A Multicentre, DoubleBlind, PlaceboControlled, Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough. 2. Willing and able to comply with study procedures 3. Able to provide written informed consent to participate 1. Any subject meeting any exclusion criteria on the study "A Multicentre, DoubleBlind, PlaceboControlled, Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough." Will be excluded from this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>chronic cough</keyword>
</DOC>